Syngene International Limited (NSE: SYNGENE) has reported a sequential revenue growth of 13% in Q2 FY27, marking a significant milestone for the company. The focus keyword, Syngene International Limited SYNGENE Q2 FY27 revenue growth, highlights this impressive financial performance. The company’s operating EBITDA margin improved by 6 percentage points, reflecting robust operational efficiency.

Strategic Initiatives

The company’s strategic initiatives have played a crucial role in achieving this growth. Syngene’s integrated drug discovery offering has been strengthened by bringing its Chemistry, Biology, and Biotherapeutics capabilities under unified leadership. This move aims to deliver a more comprehensive drug discovery offering to customers.

Global Manufacturing Expansion

A key highlight of the quarter was the signing of the first manufacturing agreement for the Bayview biologics facility in the U.S. This agreement marks an important milestone in Syngene’s large molecule manufacturing journey, reinforcing the company’s integrated India-U.S. delivery model.

Future Outlook

Syngene remains focused on enhancing its integrated drug discovery offering, sharpening commercial execution, improving asset utilization, and translating scientific capabilities into sustainable business growth. The company’s leadership is confident in the long-term potential of its investments in global manufacturing infrastructure and advanced capabilities.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Syngene International Limited

Syngene International Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Syngene trades in the lower quarter of its 52-week range. Thin margins at 6.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 1.6% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 5.4% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Syngene International Limited.

FDC Limited (NSE: FDC) today announced its unaudited consolidated financial results for the second quarter and half-year ended September 30, 2026, showcasing robust growth across segments. The company’s revenue from operations for Q2 FY27 stood at Rs. 572 crores, a year-on-year increase of 21.0% over Rs. 473 crores in Q2 FY26. Domestic Formulations grew 22.6% Y-o-Y, led by Electral and Enerzal, while International Formulations grew 28.5% Y-o-Y in Q2 and 47.6% in H1 FY27.

Domestic Formulations Lead Growth

Domestic Formulations returned to double-digit growth in Q2 FY27, with revenue of Rs. 467 crores, up 22.6% Y-o-Y from Rs. 381 crores in Q2 FY26. The recovery was driven by flagship brands Electral and Enerzal, and Zifi, which overcame earlier quarter challenges.

International Formulations Continue Momentum

International Formulations continued their growth trajectory in Q2 FY27, with sales of Rs. 75 crores, up 28.5% Y-o-Y from Rs. 58 crores in Q2 FY26. For H1 FY27, International Formulations sales rose 47.6% Y-o-Y to Rs. 148 crores, from Rs. 101 crores in H1 FY26.

API Segment Sees Decline

The API business recorded sales of Rs. 28 crores in Q2 FY27, against Rs. 30 crores in Q2 FY26 (-4.8% Y-o-Y). For H1 FY27, API sales declined 4.0% Y-o-Y to Rs. 52 crores, from Rs. 54 crores in H1 FY26, mainly due to lower sales of one key molecule.

As a result, FDC Limited (NSE: FDC) is poised for continued growth, with a strong foundation in both domestic and international markets. The company remains committed to exploring innovative solutions and expanding its healthcare horizons globally.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of FDC Limited

FDC Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

FDC falls 15.2% over three months and has not found a floor yet. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 1.50 sits close to fair value. The stock is neither a clear buy nor obviously expensive. Buyers show up with 1.4x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 6.8% and profits at 13.2%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.50 premium is usually justified. Check Fundamentals of FDC Limited.

Medplus Health Services Limited (MEDPLUS) has announced its Q2 FY2027 results, showcasing a robust performance in the quarter. The company reported a revenue of ₹20,371 million, marking a significant 21.3% year-over-year increase. The gross margin stood at 25.1%, reflecting a slight decline of 110 basis points year-over-year but a 60 basis points improvement quarter-over-quarter.

Revenue and Growth

The revenue for Q2 FY2027 was ₹20,371 million, which is ₹3,578 million higher than the same period last year. This growth is complemented by a quarter-over-quarter increase of ₹1,575 million, representing an 8.4% rise. The company also experienced a 0.6% decrease in private label revenue compared to Q2 FY26.

Store Expansion and Profitability

MEDPLUS added 166 new stores in Q2 FY2027, bringing the total store count to 5,642. Of these, 101 were net additions beyond Tier-One cities. The company’s store-level EBITDA margin improved to 11.7%, and the operating ROCE (Return on Capital Employed) stood at 72.0%.

Financial Performance

The pharmacy operating EBITDA for the quarter was ₹885 million, showing a 4.4% operating EBITDA margin, up by 120 basis points quarter-over-quarter. The company’s consolidated operating EBITDA reached ₹981 million, and the operating cash flow was ₹370 million, resulting in a 37.7% ratio of operating cash flow to operating EBITDA.

As a forward-looking statement, MEDPLUS remains optimistic about its growth trajectory, leveraging its extensive network of 5,642 stores across 13 states and 1 union territory. The company aims to further penetrate existing clusters and develop new ones, capitalize on its omni-channel strategy, and expand its private label offerings to drive higher margins and customer retention.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Medplus Health Services Limited

Medplus Health Services Limited belongs to the Healthcare › Pharmaceutical Retailers sector. Here’s a quick read on where the business and the stock stand today.

Medplus drops 23.6% over three months and trades near its 52-week lows. The PEG of 0.55 signals undervaluation relative to growth. It is a potential re-rating candidate. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. RSI stands at 26, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. The business compounds at 14.7% revenue and 64.0% profit CAGR, with D/E of 0.64. Yet the stock drops 23.6% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Medplus Health Services Limited.